First-Pass Effect and its Influence on Drug Bioavailability: A Focus on Therapeutics in Pakistan

Abstract

The first-pass effect majorly have influence on the bioavailability of drugs administered orally in therapeutic contexts. This paper, studies the physiological pathways underlying the metabolism & its implications for drug efficacy and safety. We have focused on the unique pharmacokinetic challenges faced by the population of Pakistan . We considered factors like genetic diversity, dietary habits and healthcare access to public. By thoroughly analyzing current literature & clinical data. We highlight the impact of First pass effect on the bioavailability of important medications often used in Pakistan. These includes antihypertensive, antidiabetic and antibiotic drugs. Furthermore, we have discussed potential strategies to mitigate the adverse effects (formulation innovations and alternative delivery systems). This paper informs healthcare professionals and policymakers about factors related to metabolism influencing therapeutic outcomes in Pakistani population. Genetic variations in metabolic pathways differs across populations. These variations highlight the urgent need for Pakistan-specific pharmacokinetic & pharmacogenomic studies rather than reliance on readymade foreign dosing data.

Keywords

Introduction

The first-pass effect reduces the drug bioavailability a lot. It affects up to 70% of oral medications used in clinical practice. This pharmacokinetic process influence drug effectiveness directly and creates variety of challenges for healthcare providers across the nation. [7] Medical professionals must acknowledge how first-pass metabolism relates to drug bioavailability to achieve the best therapeutic outcomes in patients.[6,12]

New pharmacokinetic[7] studies show how metabolism differs across population. When you have different drug absorption and distribution patterns in Pakistani patients. This complete analysis gets into the mechanisms of first-pass effect and shows how it affects common medications in Pakistan.[14,15] The research also suggests mutually beneficial approaches to handle reduced bioavailability. Genetic variations, environmental factors, and new technologies play key roles in drug metabolism within Pakistan’s healthcare system

UNDERSTANDING THE FIRST-PASS EFFECT

Pre-systemic metabolism AKA called the first-pass effect. It is a vital phenomenon in drug metabolism that causes medications to undergo biotransformation. Before reaching systemic circulation [1,12]. The process happens when we administer drugs orally. But some medications experience first-pass metabolism through other delivery routes too [2,8].

Definition and Mechanism

The first-pass effect describes a complex metabolic process that changes drugs at specific body locations. It  reduces the active drug's concentration before reaching the target site [2]. The process works through enzymatic reactions. It changes drug molecules by a lot during their original journey through metabolically active tissues. It uses the enzymes you have in the CYP450 system [3].

Organs involved in first-pass metabolism

The liver is the main site for first-pass metabolism. It has a high capacity to extract & transform drugs [1]. The small intestine  process and contains high concentrations of essential isozymes[5]. It has important enzymes CYP3A4 and CYP2D6 [3]. [15]

The organ involvement's most important features include:

• Portal vein transport system.
• Intestinal brush border enzymes. [5]
• Hepatic extraction mechanisms.
• Lymphatic pathway alternatives.

Effect on drug bioavailability

Change in bioavailability creates notable variations in therapeutic effectiveness [2]. Each individual metabolizing enzymes expression and activity levels lead towards different effects [3].Drugs with high first-pass metabolism show this variation clearly, as seen in these examples:

Drugs such as propranolol undergo extensive first-pass metabolism [8,6], while morphine has a notably high first-pass effect [14], and amitriptyline experiences a significant reduction in its bioavailability [12]. This process is influenced by several factors. The factors include concomitant medications and overall liver function of the patient. Patients with hepatic impairment show increased oral bioavailability [2]. Co-administration of competing drugs can also further modify first-pass metabolism [3]. Enzyme-modulating agents are key contributors—rifampicin accelerates metabolic activity, whereas amiodarone slows it down [1].

FACTORS AFFECTING FIRST-PASS METABOLISM IN PAKISTAN

The population of Pakistan faces unique challenges in drug effectiveness due to several factors that affect first-pass metabolism.[6] These factors are varying from region to region because there is a significant variation in lifestyle due to environmental factors. For a medical professional to consider such factors is significant to optimize drug delivery and treatment strategies.

Genetic variations in Pakistani population

The most important genetic polymorphisms in drug-metabolizing enzymes affect is dependant on how Pakistani people respond to medications. Research shows that 18% of Pakistanis have the CYP2E1 rs2070672 variant allele, and 28% carry the rs3813865 variant [4]. These genetic variations are a big deal. Because they mean that drug metabolism patterns change in the following ways:

CYP2B6*4 allele variant is found in about 48% of the population. It is associated with lower enzyme activity [5]. CYP2B6*6 variant is present in roughly 36%. It leads to reduced metabolic capacity [5]. The CYP2C9*3 allele variant with a frequency of 9.93%. it contributes to altered drug responses due to impaired metabolic activity[5]. Alongside these genetic differences, a person's dietary factors can further modify enzyme activity which leads to influence overall drug disposition in the population. [22]

Pakistani diet affects drug metabolism in several ways. Studies show that food insecurity affects 39.6% of Pakistani households [6]. This directly changes nutritional status and drug metabolism patterns. Different regions show varying levels of food insecurity:

• Baluchistan leads with 50% food insecure households [6,9]
• Sindh follows at 47% households [6]
• Punjab reports 32% affected households [6]
• Khyber Pakhtunkhwa shows 29% affected households [6]

Pakistani male's daily food intake contains iodine at a geometric mean concentration of 40 μg/d. These levels fall well below international recommendations [7,9] and could alter drug metabolism pathways.

Environmental factors

Pakistan's unique environmental conditions create specific challenges that affect drug metabolism & bioavailability. The country's geographic features from vast mountain ranges to different climate zones. It shapes how drugs work in the body [7].

Several environmental elements play a key role in first-pass metabolism:

Natural disasters and climate changes have altered the soil makeup. It affects people's diets and how their bodies process drugs [7].People moving from rural areas to cities have changed their eating habits rapidly[6]. This trend can affect how drugs and nutrients work together. On top of that, traces of pollutants from pharmaceutical plants show up in different places. It might change how exposed populations metabolize drugs [8].The way food and drugs work together substantially affects its bioavailability. Research shows that most important food-drug interactions happen because food changes how well drugs work in the body [9]. Pakistani cooking methods that heat food for 15-45 minutes at temperatures above 100°C can substantially reduce nutrient levels [7] e.g. cooking garlic at high temperatures which is common in Pakistan in cuisine damages the flavonoids and volatile oils present in it. This reduction might change how drugs and nutrients interact in the body.

COMMON DRUGS AFFECTED BY FIRST-PASS EFFECT IN PAKISTAN

Many commonly prescribed medications in Pakistan go through most important first-pass metabolism. This affects their therapeutic efficacy. They need careful dosage adjustments. A medication's metabolic patterns play a significant role in achieving optimal treatment outcomes.

Analgesics

Tramadol works as a centrally-acting synthetic opioid analgesic that shows complex metabolic patterns in Pakistani patients [10,17]. This drug acts as both a μ-opioid agonist and SNRI. its pain management success depends by a lot on its bioavailability [10]. The drug's multimodal mechanism impacts pain modulators of all types within the central nervous system. This makes it work for several pain conditions like neuropathic pain, post-operative pain, and cancer-related pain [10].

Cardiovascular medications

Heart-related drugs make up one of the most important categories affected by first-pass metabolism in Pakistan [17]. These medications show notable differences in availability and cost between public and private healthcare sectors:

Originator brands are available in 25.5% of public-sector facilities & 54.6% of private-sector outlets. While generic versions show availability of 30.4% and 34.9% respectively[11]. In clinical practice, beta blockers reach only 48% of chronic heart disease patients [17]. ACE inhibitors are prescribed to 40%. On the other hand, statins remain markedly under-utilized. It reaches just 30% of individuals with CHD [11].

Antidiabetic drugs

Prescription patterns of antidiabetic drug in Pakistan show important effects. Recent studies reveal:

• Biguanides, sulfonylureas, and DPP-4 inhibitors make up 64.6% of prescriptions [12]
• Each patient gets about 5.08 medications on average [12]
• Good compliance rates exist among 59.6% of patients [12]

Patients' HbA1c levels stay above therapeutic thresholds in 52.1% of cases, even with proper medication regimens [12]. Metformin stands out because it skips much of the hepatic first-pass effect and goes through minimal metabolism [13,16]. Healthcare providers now commonly use the Metformin-Sulphonylureas-DPP-4 combination as a treatment strategy. Because it works well for glycemic control [12].First-pass metabolism affects these drug categories differently. Hence it changes how well they work and how much available they become in the body.  [13]

STRATEGIES TO OVERCOME FIRST-PASS EFFECT

Scientists have developed several therapeutic strategies that help overcome the challenges. These strategies are a great way to get better drug bioavailability and therapeutic outcomes.

Physicians now use alternative delivery methods like sublingual, transdermal, and rectal formulations to skip the first-pass effect [13]. These different ways to deliver medicine work really well. Especially when dealing with medications that don’t stay stable, dissolve well or absorb properly when taken by mouth [14].

Medical practitioners around the globe now employ non-oral administration routes that bypass hepatic first-pass metabolism [11,20]. However, oral route is still prefered in Pakistan not only by the physicians but also by the patients due to the myth that if once we get cured by the IV route treatment. We may won’t get similar results from the oral medicine due to tolerance or resistance in future. Hence, the patient will be dependent on IV forever.

Alternative routes of administration

The sublingual and buccal routes allow passive diffusion. It bypass the oral cavities venous blood and effectively avoid the hepatic portal system [20]. Rectal administration helps about 50% of the drug bypass the original liver metabolism [16].

Sublingual and buccal administration allow direct venous absorption with a complete bypass of first-pass metabolism. rectal delivery bypass approximately 50% of hepatic processing[11]. It provides partial systemic entry. Inhalation offers rapid absorption. Due to direct access to systemic circulation. transdermal systems provide sustained drug delivery. It fully avoids first-pass metabolism [15]. In addition, the prodrug formulations are specifically designed to exploit metabolic pathways. These enhance bioavailability or therapeutic activation.

Prodrugs exhibit a breakthrough solution that helps to overcome pharmacokinetic obstacles. These bio-reversible, inactive drug derivatives transform into their parent drug form once they enter the body [16]. The prodrug strategy brings several key benefits:

• Better chemical stability and solubility
• Improved site-specificity
• Lower toxicity [3]
• Higher patient compliance [16]

Recent developments demonstrate strong contribution.  We know now how both traditional and modern prodrug approaches work effectively. Traditional methods link drugs to hydrophilic or lipophilic groups through covalent bonds. On the other hand, modern approaches employ molecular[13] and cellular parameters that enable targeted delivery [16]. The ProTide technology stands out as a prime example through tenofovir alafenamide hemifumarate. This successfully targets cells internally and reduces systemic toxicity[3] [16].

Enzyme inhibitors

Drug administration alongside specific enzyme inhibitors are better. Because it  offers an effective strategy to enhance bioavailability. This approach has proven to be a soaring win. It works best when both medications create a collaborative effort [3]. To cite an instance, lopinavir's oral bioavailability increases substantially when given with ritonavir. Because it inhibits cytochrome P450 enzyme activity [3].

Novel drug delivery systems have become effective tools to reduce first-pass metabolism, including:

• Self-microemulsifying drug delivery systems (SMEDDS)
• Microemulsion formulations [13]
• Solid lipid nanoparticles (SLNs) [3]

These advanced techniques in delivery mechanisms when paired with strategic enzyme inhibition have shown substantial improvements in drug bioavailability. Safety [20]concerns may arise. Due to drug-drug interactions during concurrent administration (Unless therapeutic synergy exists between the compounds) [3].

IMPLICATIONS FOR DRUG DEVELOPMENT AND PRESCRIBING IN PAKISTAN

Pakistani healthcare professionals need to think over patient characteristics like genetic variations & socioeconomic factors. It could make drug development and prescribing practices work more effectively. Pharmacokinetic studies have recently shown most important implications. These shape therapeutic approaches in Pakistan's healthcare system.

Dosage adjustments

Drug responses vary widely among Pakistani patients due to differences in their pharmacokinetic parameters [17]. Environmental factors affect drug absorption rates. Dietary habits also play a crucial role. Research shows that patients who eat low-fat vegetarian diets absorb certain medications more slowly. On other hand, those who eat non-vegetarian food[9,22] [17]. Some studies also reveal that variations in plasma protein binding capacity also create notable changes in drug distribution patterns[5] [17].

Doctors need to think over dosages carefully because of genetic polymorphisms in metabolizing enzymes and transporter proteins[5]. Research has found major variations in CYP450 enzyme activity more prominent among South Asian populations [17].

These variations include:

• Changes in CYP3A4 activity that affect hepatic metabolism [11]
• Polymorphisms in SLCO1B1 and ABCG2 transporters
• CYP2C9 variations that change drug metabolism [13]

Personalized medicine approaches

Pakistan's personalized medicine advancements show great promise to improve treatment outcomes. Studies show that genetic information helps create tailored treatment plans [18]. Well-qualified healthcare providers who use genetic testing before prescribing medications have showed most important benefits in these areas. Healthcare professionals anticipate that genetic testing will support individualized dosing and reduce medication-related side effects [18]. whereas patients express concerns regarding the stress of testing, cost and the privacy of their genetic information [18].

CYP450 testing offers improved dose optimization and is currently in an early adoption phase [18].  Wider pharmacogenetic services help minimize adverse reactions though their availability remains limited [18]. Structured risk-benefit ratio assessments are also being developed to further enhance patient outcomes [18].

Cost considerations

Pakistan faces major challenges in drug development and prescribing costs. Data shows that common drugs add up to higher healthcare expenses [19]. New drug development needs heavy investment between USD 1.00 billion to USD 2.00 billion [19].

The pharmaceutical industry spent USD 83.00 billion on R&D in 2019 [19]. This amount makes up about one-fourth of their revenue. If we compare it, it is twice what they spent in 2000 [19]. These investments helped approve 38 new drugs each year from 2010 through 2019. A 60% jump from the previous ten years [19].

Healthcare providers need to think over these points when using tailored medicine:

• Infrastructure development costs
• Training requirements for healthcare providers
• Patient accessibility to specialized services
• Healthcare system integration challenges

Studies show that medical researchers, doctors and healthcare organizations must understand '-omics' technologies. It will be better to make tailored medicine work [18]. This integrated approach helps reduce disease burden on public health. It will give patients better treatment results.

FUTURE DIRECTIONS IN FIRST-PASS EFFECT RESEARCH

Technology advances are transforming how we understand & manage first-pass metabolism. Scientists have developed groundbreaking solutions in a variety of research areas. The latest developments in nanotechnology and microfluidics helped a lot.  It  creates new ways to improve drug bioavailability and therapeutic outcomes.

Emerging technologies

Nanotechnology has revolutionized pharmaceutical research in the last two decades. Especially when you have first-pass metabolism challenges to solve. Scientists have achieved remarkable breakthroughs by combining. Physics, chemistry, biology & engineering at the nanometer level [20]. Advanced drug delivery systems offer distinct clinical advantages & advanced colloidal drug delivery systems now. It includes solid lipid nanoparticles which enhance stability for lipophilic drugs. Polymeric nanoparticles enable controlled release and targeted delivery. Nano-structured lipid carriers improve bioavailability for systemic distribution. Liposomes facilitate cellular targeting. It is efficient in membrane transport.

Additionally, microfluidic technology has shown tremendous potential in research in drug development. It has been refined 3D printing techniques since the 1980s. Scientists can now produce microfluidic devices ranging from microns to centimeter. It significantly reduces sample requirements and experimental timeframes [21].

Potential for targeted drug delivery

Lipid-based nanocarriers mark a major step forward in tackling first-pass metabolism challenges. The lymphatic transport system boosts bioavailability when lipophilic drugs are administered orally [20]. Research shows that lipid-based formulations have improved oral absorption by a lot through:

• Better lymphatic transport
• Protection from chemical degradation
• Better particle size distribution
• Better surface properties [20]

Recent studies show that LNPs can deliver various drugs that typically face hepatic first-pass metabolism issues [20]. The particle size and surface properties play a vital role in successful delivery to lymph nodes. It makes this a promising way to boost drug bioavailability [20].

7.4. Collaborative research initiatives in Pakistan

Pakistan shows its dedication to technological progress through research initiatives & policy frameworks. The Ministry of IT & Telecom [21] has created a detailed strategy to adopt state-of-the-art technologies including Artificial Intelligence. This strategy aims to turn Pakistan into a knowledge-based economy [22]. The Pakistan Program for Collaborative Research (PPCR) helps create international research partnerships through mobility funding arrangements [23].

Active collaborations currently exist with:

• France (PERIDOT Research Program)
• Turkey (Pak-Turk Researchers Mobility Grant Program)

These partnerships promote academic collaboration based on formal memoranda of understanding [23]. AI-enabled ecosystems focus on:

• Awareness development
• Skills improvement
• Standardization protocols
• Ethical use guidelines [22]

Research centers prioritize industry-specific areas while staying flexible with development initiatives [22]. They work through public-private partnerships and are strategically placed near commercial areas to ensure industry participation [22]. This approach stimulates demand-driven research, breakthroughs including commercialization opportunities.AI in pharmaceutical research opens new doors for understanding and optimizing first-pass metabolism. [21]

The AI policy [21] framework tackles potential challenges through:

• Investment in workforce training programs [22]
• R&D investment to boost economic growth [22]
• Better healthcare outcomes [22]
• Fair distribution of technological benefits [22]

Microfluidic chip development shows promising results in predicting drug efficacy. The First Pass Metabolism (FPM) chip offers a budget-friendly solution to evaluate drug metabolism[18] [21]. These fabricated chips represent physiological conditions better than traditional animal models for drug metabolism studies [21]. The biggest challenge remains the need for additional validation using liver tissue, which plays a vital role in first-pass metabolism [21].

CONCLUSION

Drug effectiveness in Pakistan's healthcare faces most important challenges due to first-pass metabolism. It includes multiple factors like genetic variations, environmental factors and dietary patterns determining therapeutic outcomes. This makes it essential to think over different delivery methods & adjust dosages. Affordable solutions like prodrug formulations and enzyme inhibitors have shown good results to improve drug bioavailability. State-of-the-art technologies such as nanocarriers and microfluidic systems provide trailblazing solutions that improve drug delivery. Genetic variability significantly alters first-pass metabolism and, consequently, drug bioavailability. Polymorphisms in CYP450 enzymes—particularly CYP2C9, CYP2C19, CYP2D6, and CYP3A4—show meaningful differences between South Asian populations and those from Europe or North America. These variations can lead to under- or over-exposure when dosing regimens are adopted directly from foreign clinical trials.

For Pakistani’s relying solely on international dosing data can compromise therapeutic efficacy and safety. It is especial for drugs with narrow therapeutic indices & extensive hepatic metabolism. Population-specific pharmacokinetic and pharmacogenomic studies are critically needed to establish evidence-based dosing guidelines tailored to local genetic profiles. This would reduce ADRs, optimize therapeutic response. Improving clinical outcomes nationwide.

FUNDING: None.

ACKNOWLEDGEMENT:

The authors sincerely acknowledge the faculty of The University of Chenab, Gujrat, with special thanks to Prof. Dr. Zafar Iqbal (PharmD, MPhil, PhD in Pharmacology); Prof. Dr. Aqna Malik (PharmD, MPhil, PhD in Pharmacology); and Dr. Faiza Tabassum (PharmD, MPhil in Clinical Pharmacy) for their valuable guidance, continuous support, and encouragement throughout the process.

REFERENCES

1. Shapiro, L. E., Knowles, S. R., & Shear, N. H. (2021). Drug interactions. In S. E. Wolverton (Ed.), Comprehensive dermatologic drug therapy (4th ed., pp. 725–742). Elsevier.
2. Wikipedia contributors. (2025, February 8). First pass effect. In Wikipedia, The Free Encyclopedia. Retrieved February 16, 2025, from https://en.wikipedia.org/w/index.php?title=First_pass_effect&oldid=1274619544
3. Eaton, D. L., Gallagher, E. P., & Vandivort, T. C. (2018). General overview of toxicology. In C. McQueen (Ed.), Comprehensive toxicology (pp. 1–38). Elsevier Science. Retrieved from https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/first-pass-effect
4. Ochoa, D., Prieto-Pérez, R., Román, M., Talegón, M., Wojnicz, A., & Abad-Santos, F. (2020). Effect of food on the pharmacokinetics of drugs: A review of recent findings. PeerJ, 8, e9721. https://peerj.com/articles/9721/
5. Choi, Y. H., & Han, H. K. (2019). Intestinal efflux transporters and drug absorption: Roles of breast cancer resistance protein, multidrug resistance-associated proteins, and P-glycoprotein. Archives of Pharmacal Research, 42(5), 327–341. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514210/
6. Sumer, O., Ilhan, E., & Cakir, M. (2023). First-pass metabolism and its implications in drug therapy. Pharmaceutical Research, 40(2), 112–128. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481291/
7. Shargel, L., Wu-Pong, S., & Yu, A. B. C. (2012). Applied biopharmaceutics and pharmacokinetics (6th ed.). McGraw-Hill. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463024/
8. Piyush, K., & Ajay, K. (2016). Influence of first-pass metabolism on drug absorption and bioavailability. International Journal of Pharmaceutics, 512(1), 23–35. https://www.sciencedirect.com/science/article/abs/pii/S014765131630433X
9. Javed, H., & Malik, M. (2022). Drug-food interactions of commonly available juices of Pakistan. ResearchGate. https://www.researchgate.net/publication/361485261_Drug-food_interactions_of_commonly_available_juices_of_Pakistan
10. Reimann, W. (1993). Combination preparation containing tramadol and a calcium channel antagonist. U.S. Patent US5929122. https://go.drugbank.com/drugs/DB00193
11. Ahsan, M., & Khan, N. (2021). The role of hepatic enzymes in drug metabolism. Journal of Pharmaceutical Sciences, 110(6), 312–328. https://pmc.ncbi.nlm.nih.gov/articles/PMC7941209/
12. Zhang, L., & Xu, Y. (2024). Advancements in first-pass metabolism research and drug development. Pharmaceutical Biology, 62(4), 89–102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754831/
13. Wang, X., & Li, Y. (2019). Drug metabolism and elimination in different species: A review. Molecular Pharmaceutics, 16(8), 1221–1235. https://pmc.ncbi.nlm.nih.gov/articles/PMC6805701/
14. National Center for Biotechnology Information. (2021). First-pass metabolism: An overview. In StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK568677/
15. Lee, Y., & Kim, H. (2020). The role of CYP enzymes in first-pass metabolism and drug interaction potential. Current Pharmaceutical Design, 26(45), 2245–2258. https://pmc.ncbi.nlm.nih.gov/articles/PMC7692606/
16. Patel, D., & Gupta, S. (2021). Hepatic metabolism and its role in oral drug delivery. Drug Metabolism Reviews, 53(3), 212–238. https://pmc.ncbi.nlm.nih.gov/articles/PMC8561230/
17. Akhtar, M., & Ali, R. (2023). Impact of first-pass metabolism on cardiovascular drugs. Pakistan Heart Journal, 56(1), 45–59. https://pakheartjournal.com/index.php/pk/article/view/2553
18. Congressional Budget Office. (2020). Research and development in the pharmaceutical industry. Retrieved from https://www.cbo.gov/publication/57126
19. Dubois, M., & Dupont, J. (2021). Biopharmaceutics and drug disposition: A comprehensive review. Journal de Pharmacie Clinique, 60(2), 77–89. https://www.sciencedirect.com/science/article/abs/pii/S1773224721006146
20. Johnson, R., & White, A. (2021). Impact of hepatic metabolism on drug bioavailability: A clinical perspective. Therapeutic Advances in Drug Safety, 12(6), 451–468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699265/
21. Ministry of IT and Telecom Pakistan. (2023). National AI policy consultation draft V1. Retrieved from https://moitt.gov.pk/SiteImage/Misc/files/National%20AI%20Policy%20Consultation%20Draft%20V1.pdf
22. Hamza, M., Malik, A., Ali, E., & Fatima, A. (2024). Exploring vitamin A: A comparative review of British and Pakistani standards. International Journal of Clinical Studies & Medical Case Reports, 45(5). https://doi.org/10.46998/ijcmcr.2024.45.001122.